SURESNES, France and MONTRÉAL, QC, Nov. 8, 2011 /CNW Telbec/ - Les
Laboratoires Servier, France (Servier) and Prognomix Inc., Canada
(Prognomix) announced today that they have entered into a research and
development agreement aimed at identifying novel targets as part of
programs meant to develop innovative type 2 diabetes and metabolic
This collaboration will rest on the discovery platform developed by
Prognomix. This platform comprises genomic and bioinformatic
technologies, a database of phenotypic and genotypic data and an
assembly of results of the analysis of these data that are at the
foundation of a knowledge base that will be exploited by the partners.
This knowledge base was developed using, among other, the data
collected during ADVANCE, the largest clinical study ever conducted on
Type 2 diabetes and of which Servier was the main sponsor.
As part of the agreement, Servier will make a contract signature fee
payment and will be granted options to obtain rights to use the results
of the collaboration.
According to Dr. Pavel Hamet, President of Prognomix, « Closing of this
agreement represents an important step in the development of Prognomix
and confirms the value of the knowledge base that we have developed. We
are happy to initiate this collaboration with Servier, a well known and
very innovative pharmaceutical company and we are excited by the
opportunities it represents ».
According to Dr. Emmanuel Canet, President of Research and Development
at Servier, « This partnership confirms Servier interest for well
validated biomarkers, allowing for the identification of the patients
who will benefit the most from Servier therapeutic innovations ».
About Prognomix Inc.
Prognomix Inc. is a privately held Personalized Medicine company
incorporated in Montreal in 2005 and focused on discovery and clinical
application of genomic signatures predictive of susceptibility to
diseases, their complications and individual therapeutic
responsiveness. The company has made significant progress in the
identification of the genomic features associated with complications of
type II diabetes (T2D). Based on these findings Prognomix has developed
a prototype of a molecular diagnostic kit that will include clinical,
genomic and epigenomic markers
About Les laboratoires Servier
Servier is a leading French independent pharmaceutical company and the
second French pharmaceutical company worldwide. Its affiliates are
present in 140 countries and account for 20,000 employees including
3,000 in research and development. www.servier.com
SOURCE Prognomix Inc.
For further information:
For Prognomix :
Normand Balthazard, CEO
1 514 248 7789
For Servier :
Direction de la Communication Institutionnelle
Tél : 01.55.72.60.37